Although most patients diagnosed with Hodgkin's lymphoma can be considered long-term disease-free survivors with first-line combined modality protocols, some prove to be primary refractory or to have relapsed disease, ultimately dying from the underlying disorder.
Hodgkin's lymphoma (HL) is a highly curable haematological malignancy with an overall survival (OS) in the early stages of around 90 % with modern first-line therapies. 1 In patients being diagnosed in advanced stages, the survival rate for 10-year OS is only above 50 %. 2 Despite advances in the treatment of HL, patients having refractory or relapsed (RR) disease still have a poor prognosis. 3 
Standard Therapy for Relapsed Hodgkin's Lymphoma
Patients having primary RR disease nowadays remain a clinical challenge. Autologous stem cell transplantation (ASCT) is considered the standard of care for patients having relapsed chemosensitive disease. Two randomised trials showed significant benefit in terms of freedom from treatment failure (FFTF) for ASCT over conventional chemotherapy (CT) in this group of patients. 4, 5 These trials have resulted in the recommendation of ASCT at the time of first relapse for even the most favourable of patients, though salvage radiotherapy (RT) can offer an effective treatment for selected subsets. is not an option after failure of at least two prior multi-agent CT regimens.
In addition, BV is also approved in patients having another CD30 positive malignancy, systemic anaplastic large cell lymphoma (sALCL), after failure of at least one prior multi-agent CT protocol. SG035-0001 trial administered BV every 3 weeks, 8 whereas SG035-0002 trial administered the drug weekly. 10 These trials explored the safety, maximum-tolerated dose (MTD) and dosing the drug once a week and every 3 weeks. Compelling clinical results with a tumour regression percentage of around 85 % were found. The interesting results seen in the phase I trial led to the development of two phase II trials, one of them evaluating the efficacy and safety of BV in patients having RR HL failing an ASCT. 11 A total of 102 patients were treated with BV 1.8 mg/ kg by intravenous infusion every 3 weeks. In the absence of disease progression or prohibitive toxicity, patients received a maximum of 16 cycles. The primary endpoint was the overall objective response rate (ORR) determined by an independent radiology review facility -75 %, with complete remission (CR) in 34 % of patients. The median progression-free survival (PFS) time for all patients was 5.6 months, and the median duration of response for those in CR was 20.5 months.
The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia and diarrhoea. (HL 17 %; sALCL 60 %), median PFS was 5.1 months and toxicity was mild to moderate in the majority of cases, including sepsis (n=5) and sensory neuropathy (n=3). Six patients proceeded to allo-SCT. Best response was seen after four doses, and the authors concluded that consideration of allo-SCT should be made early and scheduled after the first assessment indicating response. 13 The Italian group has reported the largest study published to date, including 65 heavily pretreated patients diagnosed with HL with a median age of 27.5 years. Of them, 88 % had undergone a previous ASCT, 5 % had also failed an allo-SCT and 69 % were refractory to first-line therapy.
Brentuximab Vedotin in Real Life -Results of Published Named Patient Programs
Median number of cycles of BV was eight, at a dose of 1.8 mg/kg every 3 weeks. Response was assessed by PET-CT scan after cycles 3 and 8 (PET3, PET8). ORR at the first restaging was 70.7 %, including 21.5 % of CR, indicating that consolidation should be considered early. ORR after PET8 was 45.5 %, with an OS at 20 months of 73.8 % and a median PFS of 6.8 months. Peripheral neuropathy was, again, the most common adverse event (21.5 %), though less frequent than in the pivotal phase II study. 14 The recently published Turkish experience reported similar results in a group of 58 patients having HL (median age 26) who received a median number of seven cycles of BV. Forty-nine patients had failed a prior SCT (39 ASCT and 10 allo-SCT). ORR was 63 %, with 26 % CR in the early evaluation; on treatment prolongation, the ORR was 32 %, with 22 % CR.
OS at 12 months was 71 %, with a median PFS of 7 months. Fourteen patients were subsequently transplanted, but only 36 % were in CR before the transplant. BV was well tolerated, with the most common side effects fatigue (50 %) and neuropathy (31 %). 15 Finally, the Asian experience 16 includes 22 patients (median age 30) who had previously received a median number of three prior treatments.
More than 50 % of them were primary refractory, and almost 80 % of them had failed a prior ASCT. ORR was 72.7 %, with a CR rate of 18. 
The Role of Stem Cell Transplantation in the Era of Brentuximab Vedotin
ASCT is the standard of care for patients with relapse chemosensitive disease. Not all patients perform equally after an ASCT; several welldescribed clinical factors are associated with a poorer long-term outcome after transplant. More recently, the achievement of a PET negative CR status has been associated with a significantly better outcome after ASCT, independent of the number of treatment lines needed to reach this situation. 17 The major clinical concern allo-SCT faces nowadays is not non- relapse mortality (NRM), but rather the high relapse rate that patients experience after the allogeneic procedure. The introduction of BV in these two clinical settings has allowed to significantly modify this landscape.
Brentuximab Vedotin and Autologous Stem Cell Transplantation
BV is able to facilitate patients undergoing an autologous procedure.
Sasse et al. 18 retrospectively analysed 14 patients having primary RR HL who were treated with BV as single agent in an NPP and who had not received a prior ASCT out of consideration for their refractory disease (n=9), comorbidities (n=4) or unknown factors (n=1). BV resulted in an ORR of 71 % (10/14) with five CR. Five patients having refractory disease and four patients having relevant comorbidity responded. Consolidating ASCT (n=4) or allo-SCT (n=1) was performed in five patients. Median PFS was 9 months, with the median OS not reached. These data indicated the capacity of BV to take into ASCT otherwise chemorefractory patients.
Moskowitz and co-workers 19 have tested the capacity of BV single drug per two cycles to achieve a PET-negative CR in patients having relapsed HL to avoid salvage CT before ASCT. Forty-six patients were included in this investigator-initiated strategy (45 were evaluable), all receiving two cycles of BV at the usual schedule. Twelve patients achieved a PETnegative CR after BV and underwent the ASCT procedure. The remaining 30 patients were treated with augmented ifosfamide, carboplatin and etoposide (ICE) for two cycles. Twenty-one patients achieved PETnegative status and were autografted. The eight last patients underwent different strategies, seven ending up in the ASCT programme. In total, 39 of 45 evaluable patients were able to be autografted; event-free survival of the whole series was greater than 80 %.
BV has also been tested in platinum-refractory patients with the objective of increasing the PET negativity rate before transplantation. 
Brentuximab Vedotin and Allogeneic Stem Cell Transplantation
The use of reduced-intensity conditioning (RIC) protocols has allowed a significant reduction on NRM after the allogeneic procedure. The major cause of failure of allo-SCT is disease relapse after transplantation; patients having chemosensitive disease do significantly better than patients having refractory disease. BV is an interesting treatment option for bridging patients into the allogeneic transplantation without significant haematological and extrahaematological toxicity, as opposed to conventional salvage CT, and with less disease burden, owing to the effectiveness demonstrated in the pivotal phase II trial. Chen et al. 22 retrospectively examined the records of 18 patients having RR HL who were treated in BV clinical trials to evaluate the efficacy and safety of subsequent RIC-allo. Seventeen patients had previous ASCT, six were in CR and eight were in partial remission before allo-SCT, with 12 grafts from unrelated or mismatched donors. The 1-year OS was 100 %, PFS was 92.3 % and NRM was 0 % (median follow-up 14 months). The incidence of acute GvHD was 27.8 %, and chronic GvHD was 56.3 %. BV before RICallo did not appear to adversely affect engraftment, GvHD or survival and might provide sufficient disease control to enable the allogeneic strategy.
Illidge et al. 23 have also reported 15 patients included in the two pivotal phase II studies who received a consolidative allo-SCT following BV HL relapsing after allo-SCT presents a major clinical challenge. BV has been evaluated in 25 HL patients (median age 32; age range 20-56) having recurrent disease after allo-SCT (11 unrelated donors). 25 Patients were >100 days after allo-SCT, had no active GvHD and received a median of nine (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Finally, BV has been used in combination with donor lymphocyte infusions (DLIs) in patients relapsing after an allo-SCT. 26 Four heavily pretreated patients having relapsed HL after allo-SCT a treatment algorithm combining BV infusions (1.8 mg/kg per day every 21 days) with DLI administration in an alternating regimen. Three patients free of GvHD initially thus received DLI in increasing doses that were continued as long as no signs of GvHD greater than I occurred, to a maximum of five doses. 
Summary and Future Perspectives
The advent of BV has changed the landscape of RR HL in recent years.
BV is a very effective and well-tolerated single drug for treating patients who are not candidates for an ASCT or who relapse after the procedure.
In combination with SCT, BV is able to increase the proportion of patients heading into an ASCT, as well as the quality of pretransplant responses.
In the allogeneic setting, BV also improves disease status before allo-SCT without increasing end-stage organ toxicity before the procedure.
Several questions remain -the capacity of BV to cure patients in the long run, the possibility of increasing ORR before ASCT with the combination of BV and conventional salvage strategies (or, eventually, to avoid salvage CT at all) -at least in a subset of well-responding patients to BV -and the final and mature results of the AETHERA prospective clinical trial. ■
